Cardiovascular Risk Reduction# Recommendation : Semaglutide Reason : SELECT demonstrated 20% MACE reduction with semaglutide 2.4 mg in 17,604 patients
The sublingual mucosa needs sustained contact
The platform's screening process is designed to identify not just who shouldn't receive GLP-1 therapy, but also which formulation and administration route best suits patients who are appropriate candidates
Less common but clinically significant adverse effects include acute pancreatitis, gallbladder disease, hypoglycemia (particularly when combined with insulin or sulfonylureas), acute kidney injury (especially with severe gastrointestinal losses), and changes in heart rate
You may be a great candidate for Weight Loss Injection if you want to: Semaglutide may be especially helpful for patients with obesity, insulin resistance, Type 2 diabetes, hormonal weight gain, and slowed metabolism